3SBio (HKG:1530) Has A Pretty Healthy Balance Sheet
3SBio (HKG:1530) Has A Pretty Healthy Balance Sheet
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor, when you assess how risky a company is. Importantly, 3SBio Inc. (HKG:1530) does carry debt. But is this debt a concern to shareholders?
獲得來自伯克希爾·哈撒韋的查理·芒格支持的外部基金經理李露直言不諱地表示:「最大的投資風險不是價格的波動,而是您是否會遭受永久性資本損失。」 因此,聰明的錢知道,債務——通常與破產相關——在評估一家公司風險時是一個非常重要的因素。值得注意的是,三生製藥(HKG:1530)確實揹負着債務。但這項債務對股東來說是個擔憂嗎?
When Is Debt A Problem?
什麼時候負債才是一個問題?
Debt is a tool to help businesses grow, but if a business is incapable of paying off its lenders, then it exists at their mercy. If things get really bad, the lenders can take control of the business. However, a more common (but still painful) scenario is that it has to raise new equity capital at a low price, thus permanently diluting shareholders. Of course, the upside of debt is that it often represents cheap capital, especially when it replaces dilution in a company with the ability to reinvest at high rates of return. When we think about a company's use of debt, we first look at cash and debt together.
債務是幫助企業增長的工具,但如果企業無法償還債權人的貸款,那麼它就存在於債權人的掌控之中。如果情況變得非常糟糕,債權人可以接管企業。然而,一種更常見(但仍然痛苦的)情況是,它必須以低價格籌集新的股本資金,從而永久性地稀釋股東的權益。當然,債務的好處在於,它經常代表着廉價資本,特別是當它取代在公司中能夠以高回報率再投資的稀釋時。當我們考慮一家公司使用債務的時候,我們首先看現金和債務兩者結合起來。
What Is 3SBio's Debt?
三生製藥的債務是多少?
As you can see below, 3SBio had CN¥4.17b of debt at June 2024, down from CN¥4.94b a year prior. However, it does have CN¥5.78b in cash offsetting this, leading to net cash of CN¥1.61b.
如下所示,截止到2024年6月,三生製藥的債務爲41.7億人民幣,相比於一年前的49.4億人民幣有所減少。然而,它還擁有57.8億人民幣的現金來抵消這部分債務,導致淨現金爲16.1億人民幣。

A Look At 3SBio's Liabilities
看看三生製藥的負債
According to the last reported balance sheet, 3SBio had liabilities of CN¥5.35b due within 12 months, and liabilities of CN¥1.72b due beyond 12 months. Offsetting this, it had CN¥5.78b in cash and CN¥1.25b in receivables that were due within 12 months. So its total liabilities are just about perfectly matched by its shorter-term, liquid assets.
根據最後報告的資產負債表,三生製藥的負債爲人民幣53.5億,12個月內到期的負債爲人民幣17.2億,12個月以外到期的負債爲人民幣53.5億。作爲抵消,其短期流動資產中的現金爲人民幣57.8億,12個月內到期的應收賬款爲人民幣12.5億。因此,它的總負債幾乎完全與其短期流動資產相匹配。
Having regard to 3SBio's size, it seems that its liquid assets are well balanced with its total liabilities. So while it's hard to imagine that the CN¥12.1b company is struggling for cash, we still think it's worth monitoring its balance sheet. Despite its noteworthy liabilities, 3SBio boasts net cash, so it's fair to say it does not have a heavy debt load!
考慮到三生製藥的規模,它的流動資產似乎與其總負債保持良好平衡。因此,雖然很難想象這家市值人民幣121億的公司會面臨現金困難,但我們仍然認爲值得關注其資產負債表。儘管負債引人注目,三生製藥依然擁有淨現金,所以可以公平地說,它的債務負擔不重!
On the other hand, 3SBio saw its EBIT drop by 9.4% in the last twelve months. That sort of decline, if sustained, will obviously make debt harder to handle. When analysing debt levels, the balance sheet is the obvious place to start. But it is future earnings, more than anything, that will determine 3SBio's ability to maintain a healthy balance sheet going forward. So if you're focused on the future you can check out this free report showing analyst profit forecasts.
另一方面,三生製藥在過去的12個月裏,其EBIT下降了9.4%。這種下降,如若持續,顯然會使債務更難處理。在分析債務水平時,資產負債表是顯而易見的起點。但未來的收益,比任何其他因素,都將決定三生製藥未來保持健康資產負債表的能力。因此,如果你關注未來,可以查看這份顯示分析師利潤預測的免費報告。
Finally, a business needs free cash flow to pay off debt; accounting profits just don't cut it. 3SBio may have net cash on the balance sheet, but it is still interesting to look at how well the business converts its earnings before interest and tax (EBIT) to free cash flow, because that will influence both its need for, and its capacity to manage debt. During the last three years, 3SBio produced sturdy free cash flow equating to 56% of its EBIT, about what we'd expect. This cold hard cash means it can reduce its debt when it wants to.
最後,一家企業需要自由現金流來償還債務;會計利潤並不足夠。三生製藥的資產負債表上可能有淨現金,但仍然值得關注這家企業如何將息稅前利潤(EBIT)轉換爲自由現金流,因爲這將影響其對債務的需求和管理能力。在過去三年中,三生製藥產生了強勁的自由現金流,相當於其EBIT的56%,這正是我們所期望的。這筆冷硬現金意味着它可以在需要時減少債務。
Summing Up
總之
We could understand if investors are concerned about 3SBio's liabilities, but we can be reassured by the fact it has has net cash of CN¥1.61b. So we are not troubled with 3SBio's debt use. There's no doubt that we learn most about debt from the balance sheet. However, not all investment risk resides within the balance sheet - far from it. To that end, you should be aware of the 1 warning sign we've spotted with 3SBio .
我們可以理解投資者對三生製藥的負債感到擔憂,但我們可以放心的是,它具有淨現金16.1億人民幣。因此,我們對三生製藥的債務使用並不感到困擾。毫無疑問,我們從資產負債表中學到的關於債務的信息最多。然而,並非所有的投資風險都在資產負債表中——遠非如此。爲此,你應該注意到我們發現的關於三生製藥的一個警告信號。
If, after all that, you're more interested in a fast growing company with a rock-solid balance sheet, then check out our list of net cash growth stocks without delay.
如果在所有這些之後,您更感興趣的是具有堅實資產負債表的快速增長公司,那麼不要拖延,查看我們的淨現金增長股票列表。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。